Stockscreener 앱 받기
3.15
1.61%
0.05
Replimune Group Inc 주식(REPL)의 최신 뉴스
REPL CLASS ACTION ALERT: FDA Response Letter Leads to - GlobeNewswire
Replimune Group (NASDAQ:REPL) Cut to “Underperform” at BMO Capital Markets - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Equal Weight” at Barclays - Defense World
Replimune Group (NASDAQ:REPL) Cut to “Neutral” at HC Wainwright - Defense World
[REPL] ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Replimune Group, Inc. Investors - TradingView
Replimune Group, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Lost Money on Replimune Group, Inc. (REPL)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Is Replimune Group Inc. a good long term investmentTremendous wealth creation - PrintWeekIndia
ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
REPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Ongoing Replimune Group, Inc. (REPL) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline - FinancialContent
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending - GlobeNewswire
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Replimune Group (NASDAQ:REPL) Cut to “Hold” at Leerink Partnrs - Defense World
Replimune Group (NASDAQ:REPL) Cut to Hold at Cantor Fitzgerald - Defense World
Shareholder Alert: Robbins LLP Informs Investors of The Replimune Group, Inc. Class Action - ACCESS Newswire
REPL INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Replimune Group and the Biotech Litigation Time Bomb: Evaluating Risks in a High-Stakes Sector - AInvest
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL - Business Wire
Shareholders Alert: Investigation Into Replimune Group, Inc. (REPL)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
INVESTOR ALERT: Investigation of Replimune Group, Inc. (REPL) Announced by Holzer & Holzer, LLC - GlobeNewswire
REPL STOCK NEWS: Replimune Group, Inc. (NASDAQ:REPL) is - GlobeNewswire
REPL ACTIVE INVESTIGATION: Lost Money on Replimune Group, Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against Replimune Group, Inc. (REPL) on Behalf of Investors - GlobeNewswire
What analysts say about Replimune Group Inc. stockExceptional trading results - Autocar Professional
Rosen Law Firm Encourages Replimune Group, Inc. Investors to Inquire About Securities Class Action InvestigationREPL - Morningstar
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on ... - Bluefield Daily Telegraph
Replimune (REPL) Shares Plummet After FDA Rejects Melanoma Drug, Sparking Investor ConcernsHagens Berman - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group, Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Replimune Group (REPL.O) Surges 34%—What’s Behind the Sharp Intraday Move? - AInvest
Iovance climbs after FDA rejection for Replimune’s skin cancer drug - MSN
Replimune Group Stock Drops Significantly on News of FDA Complete Response LetterKehoe Law Firm, P.C. Investigating Securities Claims on Behalf of InvestorsREPL - ACCESS Newswire
Replimune stock rebounds despite downgrades (REPL:NASDAQ) - Seeking Alpha
Fraud Investigation Opened: Levi & Korsinsky Investigates Replimune Group, Inc. (REPL) on Behalf of Shareholders - ACCESS Newswire
Replimune Viral-Based Therapy for Melanoma Rejected By FDA - Inside Precision Medicine
Replimune Shares Collapse After FDA Rejects Melanoma Therapy Application - MSN
What drives Replimune Group Inc. stock priceExplosive trading opportunities - Autocar Professional
Replimune receives CRL on BLA for RP1 for advanced melanoma - pharmaphorum
Replimune says FDA rejected its lead drug for skin cancer - MSN
BREAKING: Replimune Group, Inc. Shares Drop 70%; Securities - GlobeNewswire
Replimune Group (NASDAQ:REPL) Hits New 12-Month Low Following Analyst Downgrade - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives $21.00 Consensus Target Price from Analysts - Defense World
BMO Capital downgrades Replimune stock to Underperform after CRL - Investing.com Australia
Earnings Misses And Clinical Hurdles Rattle Major Stocks - Finimize
Barclays downgrades Replimune Group stock rating to Equalweight on FDA rejection - Investing.com Nigeria
Did You Suffer Losses in Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
Replimune Group Surges to 445th in Trading Volume with $255 Million Day Despite 77 Percent Stock Drop - AInvest
Replimune CRL Could Hold Warning For Accelerated Approvals - insights.citeline.com
Replimune (REPL) Faces Downgrade and Uncertainty in Latest Analy - GuruFocus
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Business Wire
REPL’s Financial Health: Exploring Replimune Group Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
FDA Rejection Shocks Wall Street, And Craters A Stock - Investor's Business Daily
FDA Issues CRL for RP1 in Advanced Melanoma - Targeted Oncology
0.97%
0.22%
자본화:
|
볼륨(24시간):